

David W Volk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6045463/publications.pdf>

Version: 2024-02-01

41
papers

7,749
citations

147726
31
h-index

276775
41
g-index

43
all docs

43
docs citations

43
times ranked

6842
citing authors

#	ARTICLE	IF	CITATIONS
1	Cortical inhibitory neurons and schizophrenia. <i>Nature Reviews Neuroscience</i> , 2005, 6, 312-324.	4.9	2,065
2	Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. <i>Trends in Neurosciences</i> , 2012, 35, 57-67.	4.2	892
3	Gene Expression Deficits in a Subclass of GABA Neurons in the Prefrontal Cortex of Subjects with Schizophrenia. <i>Journal of Neuroscience</i> , 2003, 23, 6315-6326.	1.7	843
4	Decreased Glutamic Acid Decarboxylase67 Messenger RNA Expression in a Subset of Prefrontal Cortical \hat{I}^3 -Aminobutyric Acid Neurons in Subjects With Schizophrenia. <i>Archives of General Psychiatry</i> , 2000, 57, 237.	13.8	622
5	Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. <i>Molecular Psychiatry</i> , 2008, 13, 147-161.	4.1	447
6	Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. <i>Biological Psychiatry</i> , 1999, 46, 616-626.	0.7	252
7	Reciprocal Alterations in Pre- and Postsynaptic Inhibitory Markers at Chandelier Cell Inputs to Pyramidal Neurons in Schizophrenia. <i>Cerebral Cortex</i> , 2002, 12, 1063-1070.	1.6	244
8	Cortical Deficits of Glutamic Acid Decarboxylase 67 Expression in Schizophrenia: Clinical, Protein, and Cell Type-Specific Features. <i>American Journal of Psychiatry</i> , 2011, 168, 921-929.	4.0	237
9	Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. <i>Psychopharmacology</i> , 2004, 174, 143-50.	1.5	224
10	GABA Transporter-1 mRNA in the Prefrontal Cortex in Schizophrenia: Decreased Expression in a Subset of Neurons. <i>American Journal of Psychiatry</i> , 2001, 158, 256-265.	4.0	202
11	Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. <i>Physiology and Behavior</i> , 2002, 77, 501-505.	1.0	149
12	Deficits in Transcriptional Regulators of Cortical Parvalbumin Neurons in Schizophrenia. <i>American Journal of Psychiatry</i> , 2012, 169, 1082-1091.	4.0	135
13	Alterations in Metabotropic Glutamate Receptor $\hat{I}1\pm$ and Regulator of G Protein Signaling 4 in the Prefrontal Cortex in Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 1489-1498.	4.0	117
14	Altered Cortical Expression of GABA-Related Genes in Schizophrenia: Illness Progression vs Developmental Disturbance. <i>Schizophrenia Bulletin</i> , 2015, 41, 180-191.	2.3	117
15	Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects. <i>Schizophrenia Research</i> , 1996, 19, 111-119.	1.1	114
16	Molecular Mechanisms and Timing of Cortical Immune Activation in Schizophrenia. <i>American Journal of Psychiatry</i> , 2015, 172, 1112-1121.	4.0	111
17	Prefrontal Cortical Circuits in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 4, 485-508.	0.8	90
18	Altered Markers of Tonic Inhibition in the Dorsolateral Prefrontal Cortex of Subjects With Schizophrenia. <i>American Journal of Psychiatry</i> , 2009, 166, 450-459.	4.0	77

#	ARTICLE	IF	CITATIONS
19	Early Developmental Disturbances of Cortical Inhibitory Neurons: Contribution to Cognitive Deficits in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 952-957.	2.3	76
20	Dysregulated ErbB4 Splicing in Schizophrenia: Selective Effects on Parvalbumin Expression. <i>American Journal of Psychiatry</i> , 2016, 173, 60-68.	4.0	70
21	The Role of the Nuclear Factor- κ B Transcriptional Complex in Cortical Immune Activation in Schizophrenia. <i>Biological Psychiatry</i> , 2019, 85, 25-34.	0.7	58
22	The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. <i>Biological Psychiatry</i> , 2016, 79, 595-603.	0.7	53
23	Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: Implications for schizophrenia. <i>Neurobiology of Disease</i> , 2013, 50, 179-186.	2.1	52
24	Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. <i>Schizophrenia Research</i> , 2014, 159, 124-129.	1.1	52
25	Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia. <i>Neuroscience</i> , 2013, 248, 154-164.	1.1	49
26	Cortical Opioid Markers in Schizophrenia and across Postnatal Development. <i>Cerebral Cortex</i> , 2012, 22, 1215-1223.	1.6	43
27	Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia. <i>Neurobiology of Disease</i> , 2017, 99, 58-65.	2.1	39
28	Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia. <i>Schizophrenia Research</i> , 2016, 177, 3-9.	1.1	36
29	Elevated Viral Restriction Factor Levels in Cortical Blood Vessels in Schizophrenia. <i>Biological Psychiatry</i> , 2014, 76, 160-167.	0.7	35
30	GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. <i>Current Neuropharmacology</i> , 2005, 3, 45-62.	1.4	33
31	Altered Expression of ARP2/3 Complex Signaling Pathway Genes in Prefrontal Layer 3 Pyramidal Cells in Schizophrenia. <i>American Journal of Psychiatry</i> , 2017, 174, 163-171.	4.0	33
32	Endocannabinoid metabolism in the prefrontal cortex in schizophrenia. <i>Schizophrenia Research</i> , 2013, 147, 53-57.	1.1	32
33	Chemokine receptors and cortical interneuron dysfunction in schizophrenia. <i>Schizophrenia Research</i> , 2015, 167, 12-17.	1.1	28
34	Effects of a mediodorsal thalamus lesion on prefrontal inhibitory circuitry: implications for schizophrenia. <i>Biological Psychiatry</i> , 2003, 53, 385-389.	0.7	23
35	Cortical Inhibitory Neuron Disturbances in Schizophrenia: Role of the Ontogenetic Transcription Factor Lhx6. <i>Schizophrenia Bulletin</i> , 2014, 40, 1053-1061.	2.3	22
36	Cortical Glutamic Acid Decarboxylase 67 Deficiency Results in Lower Cannabinoid 1 Receptor Messenger RNA Expression: Implications for Schizophrenia. <i>Biological Psychiatry</i> , 2012, 71, 114-119.	0.7	19

#	ARTICLE	IF	CITATIONS
37	Reciprocal Alterations in Regulator of G Protein Signaling 4 and microRNA16 in Schizophrenia. Schizophrenia Bulletin, 2016, 42, 396-405.	2.3	17
38	Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia. Schizophrenia Research, 2018, 201, 254-260.	1.1	12
39	Involvement of the nuclear factor- κ B transcriptional complex in prefrontal cortex immune activation in bipolar disorder. Translational Psychiatry, 2021, 11, 40.	2.4	11
40	l-Proline, GABA Synthesis and Gamma Oscillations in Schizophrenia. Trends in Neurosciences, 2016, 39, 797-798.	4.2	8
41	Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia. JAMA Psychiatry, 2019, 76, 887.	6.0	4